Back to Atlas
APotentially durableStandard research/education caution
CMP-0009
Research tool
A-1331852
Senolytic / BCL-xL
Selective senescent-cell apoptosis in susceptible cell types
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule
- Primary mechanism
- Selective BCL-xL inhibition
- Primary market use
- Senolytic research
Pharmacology
- Molecular weight (Da)
- 658.81
- Oral bioavailability
- Orally bioavailable in preclinical work; human F not established
- Half-life
- ~9.4 h IV in preclinical lead; human t1/2 not established
- Route tags
- Route-dependent / verify
- Evidence level
- Preclinical
- Clinical status
- Research tool
- Value-for-money score
- 3 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Potent BCL-xL probe; value constrained by thrombocytopenia-class concerns